AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38274236
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (ARNI + SGLT2i)
Trial: 38274292
Drug: Intermittent theta
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent theta burst stimulation (iTBS) administered to the left dorsolateral prefrontal cortex (DLPFC) for 14 days every 13 weeks
Trial: 38274414
Drug: SPL026 (21.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL026 (21.5 mg) administered as a 2-phase IV infusion over 10 minutes (6 mg/5 min and 15.5 mg/5 min)
Trial: 38274492
Drug: TAF 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF 25 mg/day with selgantolimod 3 mg orally once weekly (QW)
Trial: 38274492
Drug: Selgantolimod 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selgantolimod 1.5 mg QW
Trial: 38274807
Drug: Radical concurrent
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical concurrent chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy, followed by adjuvant immunotherapy for at least one year.
Trial: 38276920
Drug: Self-reported fair
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported fair or poor oral health
Trial: 38277156
Drug: Omnipod insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omnipod insulin delivery system
Trial: 38278170
Drug: Pozelimab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pozelimab (30 mg/kg loading dose, followed by weekly subcutaneous doses based on body weight)
Trial: 38278217
Drug: Nighttime pistachio
RxNorm normalized name: Pistachio
DrugBank: Pistachio (DB10559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nighttime pistachio snack (57 g/d)
Trial: 38278364
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester (4 g/d)
Trial: 38278856
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (CDT)
Trial: 38278960
Drug: Dasatinib for
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib for 2 years after re-treatment
Trial: 38279085
Drug: Psilocybin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (30 mg)
Trial: 38279085
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (5 mg)
Trial: 38279124
Drug: DON 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DON 0.1 mg/kg
Trial: 38279124
Drug: DON 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DON 1.0 mg/kg
Trial: 38279363
Drug: Otilimab 180
RxNorm normalized name: Otilimab
DrugBank: Otilimab (DB06303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 180 mg subcutaneously once weekly for 5 weeks, then every other week until week 10.
Trial: 38279364
Drug: Otilimab 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 22.5 mg
Trial: 38279364
Drug: Otilimab 45
RxNorm normalized name: Otilimab
DrugBank: Otilimab (DB06303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 45 mg
Trial: 38279364
Drug: Otilimab 135
RxNorm normalized name: Otilimab
DrugBank: Otilimab (DB06303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 135 mg
Trial: 38279367
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of subcutaneous anifrolumab
Trial: 38279367
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of subcutaneous anifrolumab
Trial: 38279368
Drug: Intravenous belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous belimumab (10 mg/kg)
Trial: 38279383
Drug: PF-06826647 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06826647 100 mg
Trial: 38279402
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2 intravenously)
Trial: 38279411
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg or 10 mg twice daily
Trial: 38279575
Drug: Piclidenoson 3
RxNorm normalized name: Piclidenoson
DrugBank: Piclidenoson (DB05511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piclidenoson 3 mg BID
Trial: 38279575
Drug: Piclidenoson 2
RxNorm normalized name: Piclidenoson
DrugBank: Piclidenoson (DB05511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piclidenoson 2 mg BID
Trial: 38279662
Drug: MDMA 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 0.75 mg/kg
Trial: 38279662
Drug: Methamphetamine (MA)
DrugBank: Metamfetamine (DB01577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methamphetamine (MA) 20 mg
Trial: 38279910
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy with Timothy grass (SCIT)
Trial: 38280003
Drug: AK104 (Cadonilimab)
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK104 (Cadonilimab) therapy
Trial: 38280052
Drug: Nanoemulsion curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoemulsion curcumin (NEC, 200 mg/day)
Trial: 38280118
Drug: High tone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tone therapy (HiToP 191 PNP ®)
Trial: 38280181
Drug: Atezolizumab maintenance
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab maintenance therapy
Trial: 38280281
Drug: Short-acting bronchodilator
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting bronchodilator (SAB) - 400 µg of salbutamol and 80 µg of ipratropium
Trial: 38280281
Drug: Short-acting bronchodilator
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting bronchodilator (SAB)
Trial: 38280392
Drug: Laquinimod 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod 1.0 mg
Trial: 38280448
Drug: Iruplinalkib 180
RxNorm normalized name: Iruplinalkib
DrugBank: Iruplinalkib (DB17494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iruplinalkib 180 mg once daily (7-day run-in at 60 mg once daily)
Trial: 38280653
Drug: Faricimab 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab 6.0 mg every 4 weeks for 24 weeks
Trial: 38280653
Drug: Aflibercept 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2.0 mg every 4 weeks for 24 weeks
Trial: 38281089
Drug: Vitamin-K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K antagonists (VKAs)
Trial: 38281295
Drug: Rivoceranib 700
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoceranib 700 mg once daily
Trial: 38281295
Drug: Rivoceranib 700
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoceranib 700 mg once daily in ≥4th-line therapy
Trial: 38281309
Drug: Macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan 10 mg as monotherapy or in combination with a phosphodiesterase 5 inhibitor
Trial: 38281499
Drug: Vi polysaccharide
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi-TT)
Trial: 38281579
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Trial: 38281579
Drug: Sham transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Trial: 38281914
Drug: PD-1 inhibitor-based
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor-based immunotherapy in MSI-H patients
Trial: 38282003
Drug: QL1706 plus
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1706 plus chemotherapy (with or without bevacizumab)
Trial: 38282192
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy (PTAH)
Trial: 38282258
Drug: reduction counseling
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reduction counseling + nicotine mini-lozenges + encouragement to quit starting 1 month post-randomization (preparation)
Trial: 38282258
Drug: preparation (reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preparation (reduction counseling)
Trial: 38282503
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 0.25% bupivacaine
Trial: 38283394
Drug: Perioperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative intravenous tranexamic acid (TXA)
Trial: 38284768
Drug: MINS (Myocardial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MINS (Myocardial Injury after Noncardiac Surgery) defined as TnI level >59 ng/L
Trial: 38285244
Drug: Pharmacological ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacological ascorbate (intravenous delivery reaching plasma concentrations ≈ 20 mM)
Trial: 38285244
Drug: Transferrin receptor
RxNorm normalized name: Transferrin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transferrin receptor expression
Trial: 38285445
Drug: 2-dose nonavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose nonavalent HPV vaccine administered 6 months apart
Trial: 38285445
Drug: 3-dose HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose HPV vaccine regimen administered to historical controls
Trial: 38285446
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (20 mg, followed by 10 mg every 5 minutes)
Trial: 38285446
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine sulfate (2 or 3 mg every 5 minutes)
Trial: 38285502
Drug: Remote diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote diabetes self-management education (DSME) program including live video education classes, individualized physical activity prescription and counseling, and continuous glucose and wearable physical activity monitoring.
Trial: 38286482
Drug: Reteplase (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reteplase (18 mg + 18 mg)
Trial: 38286484
Drug: 0.32 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.32 mg/kg tenecteplase
Trial: 38286618
Drug: AtoOxy (80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AtoOxy (80/5 mg)
Trial: 38286683
Drug: Daily cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cyclic enteral nutrition administered over 10 hours
Trial: 38286683
Drug: Daily cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cyclic enteral nutrition
Trial: 38286685
Drug: Trauma-focused art
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused art therapy (TFAT) intervention for 10 weeks
Trial: 38286686
Drug: Cryotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy plus compression therapy for 6 weeks after discharge from hospital
Trial: 38286691
Drug: Cooling treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling treatment for fever control within the first 48 hours of septic shock
Trial: 38286691
Drug: No cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cooling treatment for fever control within the first 48 hours of septic shock
Trial: 38286691
Drug: Cooling treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling treatment for fever control
Trial: 38286691
Drug: No cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cooling treatment for fever control
Trial: 38286736
Drug: Iliopsoas plane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iliopsoas plane block (10 mL 0.75% ropivacaine with 1:200 000 epinephrine)
Trial: 38286736
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block (10 mL normal saline)
Trial: 38286884
Drug: Adjuvant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Therapy (AT)
Trial: 38286884
Drug: FOLFIRINOX as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX as Adjuvant Therapy
Trial: 38286884
Drug: Adjuvant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Therapy (AT) Delay
Trial: 38287068
Drug: ChulaCov19 50
RxNorm normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChulaCov19 50 µg
Trial: 38287179
Drug: Gartisertib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gartisertib (250 mg QD) in cohort A2
Trial: 38287253
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency (ID) prevalence defined as serum ferritin < 100 µg/L and/or transferrin saturation coefficient (TSAT) < 20%
Trial: 38287253
Drug: CRP ≥
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP ≥ 12 mg/L
Trial: 38287253
Drug: Treatment that
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment that may influence ID/anemia
Trial: 38287346
Drug: Radionuclide therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radionuclide therapy (RNT) targeted against prostate-specific membrane antigen (PSMA)
Trial: 38287349
Drug: Standard micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard micronutrient supplement
Trial: 38287611
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg bodyweight intravenously followed by weekly subcutaneous injections of 162 mg) after 500 mg methylprednisolone intravenously for 3 days.
Trial: 38287923
Drug: Stepped collaborative
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepped collaborative care intervention including care management, cognitive behavioral therapy elements, and psychopharmacology addressing PTSD symptoms.
Trial: 38288117
Drug: 2-cycle induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-cycle induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Trial: 38288117
Drug: 2-cycle induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-cycle induction chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Trial: 38288731
Drug: Serum urate
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum urate responders (achieved serum urate < 6 mg/dL)
Trial: 38288731
Drug: Serum urate
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum urate non-responders (did not achieve serum urate < 6 mg/dL)
Trial: 38288741
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 1 × 10^6 allogeneic bone marrow-derived mesenchymal stromal cells
Trial: 38288862
Drug: Doublet regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28)
Trial: 38288862
Drug: Triplet regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28 + atezolizumab 840 mg on days 1 and 15)
Trial: 38288922
Drug: Adalimumab plus
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab plus methotrexate (adalimumab 40 mg subcutaneously every other week + methotrexate 15 mg weekly)
Trial: 38288922
Drug: Escalated methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalated methotrexate (up to 25 mg weekly)
Trial: 38288937
Drug: secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 150 mg no loading dose (NL)
Trial: 38288937
Drug: secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 150 mg NL
Trial: 38289301
Drug: Oscillatory PEP-therapy
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oscillatory PEP-therapy using Acapella DHGreen device, 10-12 hours after tracheal extubation, 3 times a day for 3 days after surgery.
Trial: 38289301
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no respiratory therapy).
Trial: 38289301
Drug: Oscillatory PEP-therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillatory PEP-therapy.
Trial: 38289666
Drug: VR therapy
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR therapy (360° VR films on a head-mounted display for up to 20 minutes every 1 to 3 days)
Trial: 38290108
Drug: Venetoclax 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 400 mg daily after initial ramp-up until progressive disease
Trial: 38290135
Drug: Add-on parsaclisib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, then once weekly thereafter (daily-to-weekly dosing)
Trial: 38290135
Drug: Add-on parsaclisib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing)
Trial: 38290135
Drug: Add-on parsaclisib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on parsaclisib (daily-to-weekly dosing)
Trial: 38290135
Drug: Add-on parsaclisib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on parsaclisib (all-daily dosing)
Trial: 38290699
Drug: Cinnamon (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (4 g/d)
Trial: 38290741
Drug: Cold application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold application (cold gel packs applied 12 times for 15 min at 2-h intervals)
Trial: 38290741
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients receiving amiodarone treatment without cold application)
Trial: 38290996
Drug: Interdisciplinary periodontal-orthodontic
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interdisciplinary periodontal-orthodontic treatment (mucogingival surgery using subepithelial connective tissue graft followed by orthodontic treatment)
Trial: 38290996
Drug: Interdisciplinary periodontal-orthodontic
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interdisciplinary periodontal-orthodontic treatment
Trial: 38291279
Drug: Bamlanivimab (BAM)
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (BAM) 175 mg + Etesevimab (ETE) 350 mg
Trial: 38291279
Drug: Bamlanivimab (BAM)
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (BAM) 700 mg + Etesevimab (ETE) 1400 mg
Trial: 38291279
Drug: Bamlanivimab (BAM)
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (BAM) 2800 mg + Etesevimab (ETE) 2800 mg
Trial: 38291279
Drug: Bamlanivimab (BAM)
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (BAM) 700 mg alone
Trial: 38291279
Drug: Bamlanivimab (BAM)
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (BAM) 350 mg + Etesevimab (ETE) 700 mg
Trial: 38291279
Drug: Bamlanivimab (BAM)
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (BAM) 700 mg + Sotrovimab 500 mg
Trial: 38291280
Drug: Kukoamine B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kukoamine B mesylate (KB) at doses of 0.005 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.24 mg/kg, 0.48 mg/kg